Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1.Children 6 months to 72 months of age.~Exclusion Criteria:Children~1. Who had been hospitalized at the time of enrollment~2. Who had any serious reaction or hypersensitivity to any vaccine component, eggs, or chicken protein~3. Who had known impairment of the immune function~4. Who had fever interfering with normal daily activities at the time of enrollment~5. Who had received licensed vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment in the study~6. Concomitant participation in another clinical study~7. Who had surgery planned during the study period that in the investigator's opinion would have interfered with the study visits schedule.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 72 Months
- Healthy Volunteers: t

Study Arms:
- aTIV (6 to <72 months) (Type: ACTIVE_COMPARATOR): Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to \<36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 \& 29
- Comparator TIV (6 to <72 months) (Type: ACTIVE_COMPARATOR): Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to \<36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 \& 29
- TIV (6 to <72 months) (Type: ACTIVE_COMPARATOR): Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to \<36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 \& 29

Based on this trial design, predict the completion outcome and termination type (if applicable).